JP2004506604A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004506604A5 JP2004506604A5 JP2001569403A JP2001569403A JP2004506604A5 JP 2004506604 A5 JP2004506604 A5 JP 2004506604A5 JP 2001569403 A JP2001569403 A JP 2001569403A JP 2001569403 A JP2001569403 A JP 2001569403A JP 2004506604 A5 JP2004506604 A5 JP 2004506604A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- lpa receptor
- embedded image
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 35
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 28
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 28
- 238000000034 method Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 description 3
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 description 3
- 101000864393 Homo sapiens Protein BUD31 homolog Proteins 0.000 description 3
- 102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 description 3
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 description 3
- 102100030160 Protein BUD31 homolog Human genes 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- NGBAXZWTIFAJKK-UHFFFAOYSA-N CC1(NC)SC1 Chemical compound CC1(NC)SC1 NGBAXZWTIFAJKK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BFVRFWIQTACAPT-KRWDZBQOSA-N N-Palmitoyl serine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(O)=O BFVRFWIQTACAPT-KRWDZBQOSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- -1 alkenyl glycerol phosphate Chemical compound 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- ILCRQWHDNXNAMG-UHFFFAOYSA-N nonadecane-9,10,11-triol phosphono dihydrogen phosphate Chemical compound OP(O)(=O)OP(=O)(O)O.C(CCCCCCC)C(C(C(O)CCCCCCCC)O)O ILCRQWHDNXNAMG-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19037000P | 2000-03-17 | 2000-03-17 | |
| PCT/US2001/008729 WO2001071022A2 (en) | 2000-03-17 | 2001-03-19 | Lpa receptor agonists and antagonists and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004506604A JP2004506604A (ja) | 2004-03-04 |
| JP2004506604A5 true JP2004506604A5 (enExample) | 2008-03-06 |
Family
ID=22701059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001569403A Pending JP2004506604A (ja) | 2000-03-17 | 2001-03-19 | Ｌｐａ受容体作用薬および拮抗薬ならびにこれらの使用法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6875757B2 (enExample) |
| EP (2) | EP1918287A3 (enExample) |
| JP (1) | JP2004506604A (enExample) |
| KR (1) | KR100874392B1 (enExample) |
| AT (1) | ATE380187T1 (enExample) |
| AU (1) | AU4926301A (enExample) |
| CA (1) | CA2402038C (enExample) |
| CY (1) | CY1107214T1 (enExample) |
| DE (1) | DE60131730T2 (enExample) |
| DK (1) | DK1263752T3 (enExample) |
| ES (1) | ES2298227T3 (enExample) |
| PT (1) | PT1263752E (enExample) |
| WO (1) | WO2001071022A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030130237A1 (en) * | 2000-03-17 | 2003-07-10 | Miller Duane D. | LPA receptor agonists and antagonists and methods of use |
| EP1918287A3 (en) * | 2000-03-17 | 2008-08-20 | The University Of Tennessee Research Corporation | LPA receptor agonists and antagonists and methods of use |
| EP1361872A4 (en) | 2000-10-03 | 2004-05-19 | Univ Virginia | NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS |
| US7064217B2 (en) | 2001-01-30 | 2006-06-20 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
| WO2002062389A1 (en) * | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| JPWO2003007991A1 (ja) * | 2001-07-17 | 2004-11-04 | 小野薬品工業株式会社 | Ｌｐａ受容体調節剤からなる膵液分泌制御剤 |
| AU2003225568A1 (en) * | 2002-02-13 | 2003-09-04 | The Scripps Research Institute | Purification of the leading front migratory cells |
| WO2003099765A1 (en) * | 2002-05-28 | 2003-12-04 | Ono Pharmaceutical Co., Ltd. | β-ALANINE DERIVATIVE AND USE THEREOF |
| DE10225651A1 (de) * | 2002-06-08 | 2003-12-24 | Aventis Pharma Gmbh | Verfahren zur Identifizierung von Agonisten oder Antagonisten für den GPR45like/GPR63 Rezeptor |
| US7300764B2 (en) | 2002-06-08 | 2007-11-27 | Sanofi-Aventis Deutschland Gmbh | Method for identifying agonists and antagonists of the GPR45-like/GPR63 receptor |
| AU2003241834A1 (en) * | 2002-06-26 | 2004-01-19 | Ono Pharmaceutical Co., Ltd. | Remedy for chronic disease |
| EP1546110A4 (en) * | 2002-07-30 | 2008-03-26 | Univ Virginia | COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE |
| EP1597581A1 (en) * | 2002-11-13 | 2005-11-23 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with endothelial differentiation, sphingolipid g-protein-coupled receptor 4 (edg4) |
| AU2003289024A1 (en) * | 2002-12-12 | 2004-06-30 | Takeda Pharmaceutical Company Limited | Novel use of edg receptors |
| US7524638B1 (en) | 2003-06-27 | 2009-04-28 | Osi Pharmaceuticals, Inc. | Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease |
| WO2005009469A1 (ja) * | 2003-07-28 | 2005-02-03 | Sumitomo Pharmaceuticals Co., Ltd. | 新規血糖調節薬及びそのスクリーニング方法 |
| AU2004278042B2 (en) * | 2003-10-09 | 2012-02-09 | University Of Tennessee Research Foundation | LPA receptor agonists and antagonists and methods of use |
| WO2005041899A2 (en) * | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
| US7820703B2 (en) | 2004-05-06 | 2010-10-26 | University Of Virginia Patent Foundation | Lysophosphatidic acid receptor selective antagonists |
| US20060223866A1 (en) * | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
| JP2008509931A (ja) * | 2004-08-13 | 2008-04-03 | プレーシス ファーマスーティカルズ インコーポレイテッド | スフィンゴシン−１−ホスフェート（ｓ１ｐ）レセプター活性を調節するための方法および組成物 |
| EP1827606A2 (en) * | 2004-12-06 | 2007-09-05 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
| BRPI0607435A2 (pt) * | 2005-02-14 | 2010-04-06 | Univ Virginia | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, e, uso de um composto |
| JP2009502790A (ja) | 2005-07-19 | 2009-01-29 | ザ ユニバーシティー オブ テネシー リサーチ ファウンデーション | Ｃｆｔｒのｌｐａ２受容体アゴニスト阻害因子 |
| EP1986623A2 (en) | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
| JP2009526073A (ja) | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−１−リン酸受容体アナログ |
| EP2097371A2 (en) * | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| NZ576893A (en) | 2006-11-21 | 2012-01-12 | Univ Virginia Patent Found | Tetralin analogs having sphingosine 1-phosphate agonist activity |
| JP2010510250A (ja) * | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ |
| NZ580707A (en) | 2007-05-04 | 2011-11-25 | Marina Biotech Inc | Acylated cationic amino acids and uses thereof |
| CN101358609A (zh) * | 2007-08-03 | 2009-02-04 | 富准精密工业(深圳)有限公司 | 风扇转子 |
| WO2010016590A1 (ja) * | 2008-08-07 | 2010-02-11 | 国立大学法人 長崎大学 | 全身性疼痛症候群の治療または予防薬 |
| US9034820B2 (en) | 2011-03-14 | 2015-05-19 | Hsinyu Lee | Method and composition for modulating erythropoiesis |
| PH12014500355A1 (en) | 2011-08-15 | 2014-03-31 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
| EP2858635A1 (en) * | 2012-06-11 | 2015-04-15 | The Regents of The University of California | Inhibitors of hippo-yap signaling pathway |
| EP3089986B1 (en) * | 2013-12-30 | 2019-06-26 | Rxbio Inc. | Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB861463A (en) * | 1957-05-03 | 1961-02-22 | Ciba Ltd | Process for the manufacture of phosphoric acid esters and piperazine and morpholine derivatives |
| US3639571A (en) * | 1970-01-29 | 1972-02-01 | Samuel Turesky | Composition and method for retarding plaque and dental calculus |
| JPS5687590A (en) * | 1979-12-19 | 1981-07-16 | Yoshitomi Pharmaceut Ind Ltd | Diphosphoglycerine derivative |
| JPS59104310A (ja) * | 1982-12-07 | 1984-06-16 | Lion Corp | 口腔用組成物 |
| US4670575A (en) * | 1984-06-05 | 1987-06-02 | Kao Corporation | Process for purification of phosphoric mono esters |
| EP0340759A1 (en) * | 1988-05-06 | 1989-11-08 | MAGIS FARMACEUTICI S.p.A. | Salts of O-mono (di)-acetyl-glycero-mono-(bis)-(di)-phosphates of L-acetyl-carnitine and of L-acetyl carnitine esters |
| WO1990010014A1 (fr) * | 1989-02-28 | 1990-09-07 | Teijin Limited | Nouveau derive de vitamine b12, sa production et son application |
| JPH02250892A (ja) * | 1989-03-24 | 1990-10-08 | Idemitsu Kosan Co Ltd | 新規フェロセン誘導体，それを含有する界面活性剤及び有機薄膜の製造方法 |
| CA2072249C (en) | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US5565439A (en) | 1992-11-24 | 1996-10-15 | The Procter & Gamble Company | Methods of using lysophosphatidic acid for treating hyperproliferative conditions |
| EP0692975A4 (en) * | 1993-04-08 | 2000-11-29 | Univ Queensland | ADMINISTRATION OF A VASO-ACTIVE AGENT AND A THERAPEUTIC AGENT |
| US5480877A (en) * | 1993-11-02 | 1996-01-02 | Wisconsin Alumni Research Foundation | Use of lysophosphatidic acids to enhance fibronectin binding |
| GB9618634D0 (en) | 1996-09-06 | 1996-10-16 | Univ Southampton | Anti cancer drugs |
| EP1024812B1 (en) * | 1997-03-19 | 2007-01-24 | Sky High, LLC | Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof |
| CA2301921A1 (en) | 1997-08-20 | 1999-02-25 | John Graham Goddard | Compositions containing polyethylene glycol and uses thereof |
| US5945522A (en) * | 1997-12-22 | 1999-08-31 | Genset | Prostate cancer gene |
| EP1069895A4 (en) | 1998-03-18 | 2002-07-31 | Lxr Biotechnology Inc | COMPOSITIONS CONTAINING LYSOPHOSPHATIDE ACIDS THAT INHIBIT APOPTOSIS AND USES THEREOF |
| EP1918287A3 (en) * | 2000-03-17 | 2008-08-20 | The University Of Tennessee Research Corporation | LPA receptor agonists and antagonists and methods of use |
-
2001
- 2001-03-19 EP EP07122187A patent/EP1918287A3/en not_active Withdrawn
- 2001-03-19 KR KR1020027012236A patent/KR100874392B1/ko not_active Expired - Fee Related
- 2001-03-19 ES ES01922465T patent/ES2298227T3/es not_active Expired - Lifetime
- 2001-03-19 US US09/811,838 patent/US6875757B2/en not_active Expired - Fee Related
- 2001-03-19 AT AT01922465T patent/ATE380187T1/de not_active IP Right Cessation
- 2001-03-19 CA CA2402038A patent/CA2402038C/en not_active Expired - Fee Related
- 2001-03-19 JP JP2001569403A patent/JP2004506604A/ja active Pending
- 2001-03-19 PT PT01922465T patent/PT1263752E/pt unknown
- 2001-03-19 AU AU4926301A patent/AU4926301A/xx not_active Withdrawn
- 2001-03-19 WO PCT/US2001/008729 patent/WO2001071022A2/en not_active Ceased
- 2001-03-19 DK DK01922465T patent/DK1263752T3/da active
- 2001-03-19 DE DE60131730T patent/DE60131730T2/de not_active Expired - Lifetime
- 2001-03-19 EP EP01922465A patent/EP1263752B1/en not_active Expired - Lifetime
-
2005
- 2005-02-28 US US11/067,884 patent/US20050261252A1/en not_active Abandoned
-
2008
- 2008-02-26 CY CY20081100222T patent/CY1107214T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004506604A5 (enExample) | ||
| CA2402038A1 (en) | Lpa receptor agonists and antagonists and methods of use | |
| JP6664385B2 (ja) | Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類 | |
| RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
| RU2009102243A (ru) | Производные камптотецина с противоопухолевой активностью | |
| RU2009149210A (ru) | Ингибиторы днк-зависимой протеинкиназы (днк-пк) | |
| CN101309917A (zh) | 具有增强治疗性质的胃h+，k+－atp酶氘代抑制剂 | |
| JP2003531821A5 (enExample) | ||
| JP2006507235A5 (enExample) | ||
| RU2000127751A (ru) | Противоопухолевое средство | |
| JP2001526218A5 (enExample) | ||
| RU2008119842A (ru) | Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1 | |
| JP2006505543A5 (enExample) | ||
| JP2017535514A (ja) | Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類 | |
| CA2369588A1 (en) | Anticancer calcium channel blockers | |
| JP2004503564A5 (enExample) | ||
| JP2017529353A (ja) | Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類 | |
| DK1463487T3 (da) | Liposomal afgivelse af vitamin-E baserede forbindelser | |
| KR890701587A (ko) | 골 손실에 관련된 질병 치료용 이미다조(1,2-a)(피리 | |
| WO2020061470A1 (en) | Novel quinazoline egfr inhibitors | |
| RU96111012A (ru) | Пролекарства производных паклитаксела | |
| CA2302226A1 (en) | Camptothecin analogs and methods of preparation thereof | |
| RU2004105144A (ru) | Комбинации, включающие эпотилоны, и их фармацевтическое применение | |
| JP2003506455A5 (enExample) | ||
| TR200103856T2 (tr) | Naftiridin türevleri, bunların preparasyon işlemleri, kullanımları ve farmasötik kompozisyonlar. |